- Pembrolizumab in therapy of metastatic melanoma2016 | Publication without faculty affiliation
- Metastatic melanoma - when and how it should by treated2016 | Publication without faculty affiliation
- Dabrafenib in the treatment of metastatic melanoma +12015 | Publication without faculty affiliation
- Advances in the treatment of metastatic melanoma2018 | First Faculty of Medicine
- Advances in the treatment of metastatic melanoma2013 | Publication without faculty affiliation
- Nivolumab in the treatment of metastatic melanoma2015 | Publication without faculty affiliation
- Case report of a patient with metastatic melanoma treated with several lines of systemic treatment2021 | First Faculty of Medicine
- Modern immune modulation in metastatic melanoma2012 | Third Faculty of Medicine
- Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report2020 | Faculty of Pharmacy in Hradec Králové
- Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma2016 | Third Faculty of Medicine, Second Faculty of Medicine
- Targeted therapy in metastatic melanoma2014 | Publication without faculty affiliation
- More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments2017 | Publication without faculty affiliation
- Immunotherapy for metastatic melanoma2015 | Publication without faculty affiliation
- Metastatic melanoma successfully treated with Ipilimumab2012 | Third Faculty of Medicine
- Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries2018 | Third Faculty of Medicine
- Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis2017 | Publication without faculty affiliation
- Metastatic melanoma, treatment2005 | Publication without faculty affiliation
- Monitoring and safety profile in targeted treatment in metastatic melanoma2020 | Publication without faculty affiliation
- An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system2019 | First Faculty of Medicine
- Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma2022 | Faculty of Medicine in Hradec Králové
- Complete remission of two patients with metastatic melanoma on ipilimumab2012 | Publication without faculty affiliation
- Research Report University Hospital for clinical assessment GO28141Publication without faculty affiliation
- Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma2022 | Faculty of Medicine in Pilsen
- Výzkumná zpráva Fakultní nemocnice ke klinickému Hodnocení CA209-067Publication without faculty affiliation
- Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study2014 | Publication without faculty affiliation
- Effect of target therapy with BRAF and MEK inhibitors on the immune system in metastatic melanoma2023 | First Faculty of Medicine
- A long-term survivor female patient with metastatic melanoma after treatment with pembrolizumab in the third line2020 | First Faculty of Medicine
- Metastatic melanoma detected by 99mtc-sestamibi spect/ct imaging during differentiated thyroid cancer follow-up2016 | Faculty of Medicine in Hradec Králové
- Targeted treatment of metastatic melanoma in a drug-addicted patient with pre-existing hepatitis C2019 | Third Faculty of Medicine